Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Holdings Lessened by Integral Health Asset Management LLC

Integral Health Asset Management LLC reduced its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 80.0% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 10,000 shares of the medical equipment provider’s stock after selling 40,000 shares during the quarter. Integral Health Asset Management LLC’s holdings in Intuitive Surgical were worth $4,448,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the company. One Wealth Management Investment & Advisory Services LLC lifted its position in Intuitive Surgical by 3.4% in the 2nd quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock valued at $310,000 after purchasing an additional 23 shares during the last quarter. Indiana Trust & Investment Management CO lifted its position in Intuitive Surgical by 5.3% in the 2nd quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after purchasing an additional 25 shares during the last quarter. Hoxton Planning & Management LLC lifted its position in Intuitive Surgical by 4.9% in the 2nd quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $238,000 after purchasing an additional 25 shares during the last quarter. First Affirmative Financial Network lifted its position in Intuitive Surgical by 2.7% in the 2nd quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock valued at $443,000 after purchasing an additional 26 shares during the last quarter. Finally, Moors & Cabot Inc. lifted its position in Intuitive Surgical by 2.3% in the 2nd quarter. Moors & Cabot Inc. now owns 1,159 shares of the medical equipment provider’s stock valued at $516,000 after purchasing an additional 26 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors.

Insider Transactions at Intuitive Surgical

In other news, EVP Robert Desantis sold 188 shares of the business’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the sale, the executive vice president now directly owns 5,506 shares in the company, valued at $2,655,048.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, EVP Robert Desantis sold 188 shares of the business’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the sale, the executive vice president now directly owns 5,506 shares in the company, valued at $2,655,048.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The disclosure for this sale can be found here. Over the last three months, insiders sold 53,120 shares of company stock worth $25,528,753. 0.90% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have commented on ISRG shares. The Goldman Sachs Group started coverage on shares of Intuitive Surgical in a research note on Thursday, May 30th. They set a “buy” rating and a $500.00 target price on the stock. Evercore ISI lowered their target price on shares of Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a research note on Friday, July 19th. JPMorgan Chase & Co. raised their target price on shares of Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. Redburn Atlantic raised shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and raised their target price for the company from $380.00 to $510.00 in a research note on Friday, August 2nd. Finally, Truist Financial raised their target price on shares of Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $446.45.

Intuitive Surgical Stock Down 0.8 %

NASDAQ ISRG opened at $486.20 on Monday. The stock has a market capitalization of $172.46 billion, a PE ratio of 87.76, a price-to-earnings-growth ratio of 5.41 and a beta of 1.39. The company has a 50 day moving average price of $468.01 and a two-hundred day moving average price of $425.38. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $496.18.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. The firm had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company’s revenue was up 14.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.18 earnings per share. As a group, equities analysts anticipate that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.